- Condition: Diabetic Patients
Interventions: Drug: TAK-875; Drug: TAK-875; Drug: Glimepiride; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Not yet recruiting - verified May 2012 - Condition: Post-Stroke Cognitive Impairment (PSCI)
Interventions: Drug: Actovegin; Drug: Placebo
Sponsors: Nycomed; Nycomed
Not yet recruiting - verified April 2012 - Conditions: Gastric Ulcer; Duodenal Ulcer
Intervention: Drug: TAK-438
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Not yet recruiting - verified April 2012 - Conditions: Gastric Ulcer; Duodenal Ulcer
Intervention: Drug: TAK-438
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Not yet recruiting - verified April 2012 - Condition: Depressive Disorder, Major
Interventions: Drug: LuAA21004; Drug: Duloxetine; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Conditions: Type 2 Diabetes; Coronary Heart Disease
Intervention: Drug: pioglitazone
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; Takeda Pharmaceuticals North America, Inc.
Completed - verified April 2012 - Condition: Angina
Interventions: Drug: Febuxostat; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified April 2012 - Condition: Glycemic Control
Interventions: Drug: TAK-875; Drug: Sitagliptin; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Centre (Europe) Ltd.
Recruiting - verified May 2012 - Condition: Premenopausal Breast Cancer
Interventions: Drug: TAP-144-SR(6M); Drug: TAP-144-SR(3M)
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: TAP-144-SR(6M); Drug: TAP-144-SR(3M)
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified April 2012 - Condition: Hypercholesterolemia With Concomitant Type 2 Diabetes
Interventions: Drug: Atorvastatin; Drug: Rosuvastatin
Sponsors: Listen Trial Group; Listen Trial Group
Recruiting - verified April 2012 - Condition: Diabetes Mellitus
Interventions: Drug: Alogliptin; Drug: Insulin
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified May 2012 - Condition: H. Pylori Infection
Interventions: Drug: TAK-438; Drug: Lansoprazole; Drug: Amoxicillin; Drug: Clarithromycin
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified May 2012 - Conditions: Asthma; Gastroesophageal Reflux Disease
Intervention:
Sponsors: Children's Center for Digestive Health Care; Children's Center for Digestive Health Care; Takeda Pharmaceuticals North America, Inc.
Active, not recruiting - verified February 2012 - Condition: Hypertension
Interventions: Drug: Febuxostat; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Pharmacokinetics
Intervention: Drug: TAK-875 and Glimepiride
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2012 - Conditions: Hypertension; Diabetes
Interventions: Drug: Placebo; Drug: Azilsartan medoxomil; Drug: Azilsartan medoxomil
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Conditions: COPD; Chronic Obstructive Pulmonary Disease
Interventions: Drug: Roflumilast; Drug: Placebo
Sponsors: Nycomed; Nycomed
Recruiting - verified May 2012 - Condition: Bleeding
Interventions: Drug: TachoSil®; Drug: Surgicel® Original
Sponsors: Nycomed; Nycomed; Baxter US
Recruiting - verified April 2012 - Conditions: Congenital Heart Disease; Cardiac Catheterization
Interventions: Drug: saline with propofol; Drug: ketamine with propofol; Drug: ketamine with propofol
Sponsors: Ibaraki Children's Hospital; Ibaraki Children's Hospital
Recruiting - verified January 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875; Drug: TAK-875; Drug: Glimepiride
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Conditions: Chronic Kidney Disease; Anemia
Intervention: Drug: peginesatide injection
Sponsors: Affymax; Affymax; Takeda Pharmaceutical Company Limited
Active, not recruiting - verified February 2012 - Condition: Bipolar Disorder
Interventions: Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Acute Depressive Episode
Interventions: Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Conditions: Prehypertension; Gout; Pulse Wave Velocity; Hypertension; 24 Hour Blood Pressure
Intervention: Drug: Febuxostat
Sponsors: University of California, San Diego; University of California, San Diego; Takeda Global Research & Development Center, Inc.
Recruiting - verified November 2011 - Condition: Non-erosive Gastroesophageal Reflux Disease
Interventions: Drug: TAK-438; Drug: TAK-438; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified December 2011 - Condition: Erosive Esophagitis
Interventions: Drug: TAK-438; Drug: TAK-438; Drug: Lansoprazole
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified January 2012 - Condition: Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Interventions: Drug: Roflumilast; Drug: Placebo
Sponsors: Nycomed; Nycomed
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: TAK-875; Drug: TAK-875
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Drug: Pioglitazone; Drug: Pioglitazone; Drug: Pioglitazone; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Essential Hypertension
Interventions: Drug: Azilsartan medoxomil; Drug: Azilsartan medoxomil and chlorthalidone; Drug: Azilsartan medoxomil and chlorthalidone
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Centre (Europe) Ltd.
Recruiting - verified January 2012 - Condition: Chronic Idiopathic Constipation
Intervention: Drug: Lubiprostone
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center; Takeda Pharmaceuticals North America, Inc.
Not yet recruiting - verified November 2011 - Condition: Diabetes Mellitus
Intervention: Drug: Alogliptin
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified February 2012 - Condition: Bronchial Asthma
Intervention: Drug: Ciclesonide
Sponsors: Nycomed; Nycomed
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Intervention:
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Juvenile Diabetes Research Foundation; Amylin Pharmaceuticals, Inc.; Merck; Pfizer; Eli Lilly and Company; Takeda Global Research & Development Center, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Novartis
Recruiting - verified October 2011 - Conditions: Gastric Ulcers; Duodenal Ulcers
Interventions: Drug: TAK-438; Drug: Placebo; Drug: TAK-438; Drug: Placebo; Drug: Lansoprazole; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified January 2012 - Conditions: Gastric Ulcers; Duodenal Ulcers
Interventions: Drug: TAK-438; Drug: Placebo; Drug: TAK-438; Drug: Placebo; Drug: Lansoprazole; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified January 2012 - Condition: Gastric Ulcer
Interventions: Drug: TAK-438; Drug: Placebo; Drug: Lansoprazole; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified May 2012 - Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal UlcerCondition: Duodenal Ulcer
Interventions: Drug: TAK-438; Drug: Placebo; Drug: Lansoprazole; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified May 2012 - Conditions: Gastric Ulcers; Duodenal Ulcers
Interventions: Drug: TAK-438; Drug: Placebo; Drug: TAK-438; Drug: Placebo; Drug: Lansoprazole; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified January 2012 - Conditions: Gastric Ulcers; Duodenal Ulcers
Interventions: Drug: TAK-438; Drug: Placebo; Drug: TAK-438; Drug: Placebo; Drug: Lansoprazole; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified January 2012 - Condition: Erosive Esophagitis
Interventions: Drug: TAK-438; Drug: Placebo; Drug: Lansoprazole; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified January 2012 - Condition: Erosive Esophagitis
Interventions: Drug: TAK-438; Drug: TAK-438
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified January 2012 - Condition: Diabetes Mellitus
Interventions: Drug: TAK-875; Drug: TAK-875; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified January 2012 - Condition: Diabetes Mellitus
Interventions: Drug: TAK-875; Drug: TAK-875
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified January 2012 - Condition: Diabetes Mellitus
Interventions: Drug: TAK-875; Drug: TAK-875
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified January 2012 - Condition: Diabetes Mellitus
Intervention: Drug: SYR-472
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified January 2012 - Condition: Endometriosis
Interventions: Drug: Placebo; Drug: TAK-385; Drug: TAK-385; Drug: TAK-385; Drug: Leuprorelin acetate
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified February 2012 - Condition: Uterine Fibroids
Interventions: Drug: TAK-385; Drug: TAK-385; Drug: TAK-385; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified January 2012 - Condition: Endometriosis
Interventions: Drug: Placebo; Drug: TAK-385; Drug: TAK-385; Drug: TAK-385; Drug: Leuprorelin acetate
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified April 2012 - Conditions: Break Through Pain; Cancer
Intervention: Drug: Intranasal Fentanyl Spray (INFS)
Sponsors: Nycomed; Nycomed
Recruiting - verified May 2012 - Condition: COPD
Intervention:
Sponsors: Nycomed; Nycomed
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: TAK-875; Drug: TAK-875; Drug: Sitagliptin; Drug: TAK-875 and Sitagliptin; Drug: TAK-875 and Sitagliptin
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Active, not recruiting - verified May 2012 - Condition: Gout
Intervention:
Sponsors: Minneapolis Veterans Affairs Medical Center; jasvinder singh; Department of Veterans Affairs; Takeda Global Research & Development Center, Inc.; Novartis; Regeneron Pharmaceuticals
Active, not recruiting - verified April 2012 - Condition: Major Depressive Disorder
Intervention: Drug: Lu AA21004
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified November 2011 - Condition: Pharmacokinetics and Pharmacodynamics
Interventions: Drug: Alogliptin; Drug: Alogliptin; Drug: Alogliptin
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center (Asia) Pte. Ltd
Completed - verified September 2011 - Condition: Immunization
Interventions: Biological: TAK-816+ DPT-TAKEDA; Biological: ActHIB+ DPT-TAKEDA
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Active, not recruiting - verified March 2012 - Condition: Treatment Outcome
Interventions: Drug: Lu AA21004; Drug: Escitalopram
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2012


